ArticleThe American journal of pathology2000
Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice.
Article in The American journal of pathology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 62 citations in OpenAlex.
- YTH NCells · 2025Article
- Apolipoproteins as potential communicators play an essential role in the pathogenesis and treatment of early atherosclerosis.International journal of biological sciences · 2023Review
- Surfactant Protein A, a Novel Regulator for Smooth Muscle Phenotypic Modulation and Vascular Remodeling-Brief Report.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- ApoER2 (Apolipoprotein E Receptor-2) Deficiency Accelerates Smooth Muscle Cell Senescence via Cytokinesis Impairment and Promotes Fibrotic Neointima After Vascular Injury.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Atherogenesis in the Carotid Artery with and without Interrupted Blood Flow of Two Hyperlipidemic Mouse Strains.Journal of vascular research · 2019Article
- Accelerated atherogenesis in completely ligated common carotid artery of apolipoprotein E-deficient mice.Oncotarget · 2017Article
- Lysophosphatidic acid-induced vascular neointimal formation in mouse carotid arteries is mediated by the matricellular protein CCN1/Cyr61.American journal of physiology. Cell physiology · 2016Article
- A murine model of arterial restenosis: technical aspects of femoral wire injury.Journal of visualized experiments : JoVE · 2015Article
- PDZK1 prevents neointima formation via suppression of breakpoint cluster region kinase in vascular smooth muscle.PloS one · 2015Article
- Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice.Journal of the American Heart Association · 2014Article
- Hepatic overexpression of the prodomain of furin lessens progression of atherosclerosis and reduces vascular remodeling in response to injury.Atherosclerosis · 2014Article
- Type VIII collagen mediates vessel wall remodeling after arterial injury and fibrous cap formation in atherosclerosis.The American journal of pathology · 2013Article
- Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222.Atherosclerosis · 2013Article
- Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia.Toxicological sciences : an official journal of the Society of Toxicology · 2010Article
- Erythropoietin increases expression and function of vascular copper- and zinc-containing superoxide dismutase.Hypertension (Dallas, Tex. : 1979) · 2010Article
- Smooth muscle LDL receptor-related protein-1 inactivation reduces vascular reactivity and promotes injury-induced neointima formation.Arteriosclerosis, thrombosis, and vascular biology · 2009Article
- Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury.Peptides · 2009Article
- Morelloflavone blocks injury-induced neointimal formation by inhibiting vascular smooth muscle cell migration.Biochimica et biophysica acta · 2009Article
- Intimal hyperplasia in murine models.Current drug targets · 2008Review
- Apolipoprotein E inhibition of vascular hyperplasia and neointima formation requires inducible nitric oxide synthase.Journal of lipid research · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The potential cytostatic function of apolipoprotein (apo) E in vivo was explored by measuring neointimal hyperplasia in response to vascular injury in apoE-deficient and apoE-overexpressing transgenic mice. Results showed a significant increase in medial thickness, medial area, and neointimal formation after vascular injury in both apoE knockout and wild-type C57BL/6 mice. Immunochemical analysis with smooth muscle alpha-actin-specific antibodies revealed that the neointima contained proliferating smooth muscle cells. Neointimal area was 3.4-fold greater, and the intima/medial ratio as well as stenotic luminal area was more pronounced in apoE(-/-) mice than those observed in control mice (P < 0.05). The human apoE3 transgenic mice in FVB/N genetic background were then used to verify a direct effect of apoE in protection against neointimal hyperplasia in response to mechanically induced vascular injury. Results showed that neointimal area was reduced threefold to fourfold in mice overexpressing the human apoE3 transgene (P < 0.05). Importantly, suppression of neointimal formation in the apoE transgenic mice also abolished the luminal stenosis observed in their nontransgenic FVB/N counterparts. These results documented a direct role of apoE in modulating vascular response to injury, suggesting that increasing apoE level may be beneficial in protection against restenosis after vascular surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.